Haloprogin

361.39093

361.39

212-286-6

AIU7053OWL

100071

DTXSID9046865

C65842

D - Dermatologicals

9.23000

4.42150

Solid

1.959g/cm3

113.5 °C

391.9ºC at 760 mmHg

190.8ºC

1.657

6.01e-03 g/L

LD50 in mice: >3 g/kg orally and s.c.; 510 mg/kg i.p. (Seki, 1963)

22-36/37/38

26-36

KO1225000

Xn

Used to treat fungal (Tinea) skin infections such as athlete's foot, jock itch, ringworm, and tinea versicolor.

Used as a topical ointment or cream in the treatment of Tinea infections. Tinea infections are superficial fungal infections caused by three species of fungi collectively known as dermatophytes (Trichophyton, Microsporum and Epidermophyton). Commonly these infections are named for the body part affected, including tinea corporis (general skin), tinea cruris (groin), and tinea pedis (feet).

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)

Haloprogin is a halogenated phenolic ether administered topically for dermotaphytic infections. The mechanism of action is unknown, but is thought to be via inhibition of oxygen uptake and disruption of yeast membrane structure and function. There is a higher incidence of cutaneous side effects with haloprogin, including irritation, burning, vesiculation (blisters), scaling, and itching. It is generally used when the infection is unresponsive to other antifungals.

3-iodo-2-propynyl 2,4,5-trichlorophenyl ether

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients